Collectively, these findings identify NLRP3 as a key mediator of dopaminergic neurodegeneration driven by α-synuclein pathology, mitochondrial toxins, and inflammatory stress, supporting its relevance as a therapeutic target in PD. Here, NLRP3 is linked to Parkinson disease.